- Home
- TCS vs CANF Comparison
TCS vs CANF Comparison
Compare TCS & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCS
- CANF
- Stock Information
- Founded
- TCS 1978
- CANF 1994
- Country
- TCS United States
- CANF Israel
- Employees
- TCS N/A
- CANF N/A
- Industry
- TCS Catalog/Specialty Distribution
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- TCS Consumer Discretionary
- CANF Health Care
- Exchange
- TCS Nasdaq
- CANF Nasdaq
- Market Cap
- TCS 14.3M
- CANF 14.4M
- IPO Year
- TCS 2013
- CANF N/A
- Fundamental
- Price
- TCS $2.62
- CANF $1.45
- Analyst Decision
- TCS Hold
- CANF Strong Buy
- Analyst Count
- TCS 1
- CANF 2
- Target Price
- TCS $15.00
- CANF $14.00
- AVG Volume (30 Days)
- TCS 130.5K
- CANF 77.8K
- Earning Date
- TCS 10-29-2024
- CANF 12-10-2024
- Dividend Yield
- TCS N/A
- CANF N/A
- EPS Growth
- TCS N/A
- CANF N/A
- EPS
- TCS N/A
- CANF N/A
- Revenue
- TCS $799,372,000.00
- CANF $667,000.00
- Revenue This Year
- TCS N/A
- CANF $409.56
- Revenue Next Year
- TCS $2.37
- CANF N/A
- P/E Ratio
- TCS N/A
- CANF N/A
- Revenue Growth
- TCS N/A
- CANF N/A
- 52 Week Low
- TCS $1.79
- CANF $1.87
- 52 Week High
- TCS $37.80
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- TCS 27.17
- CANF 34.19
- Support Level
- TCS $1.79
- CANF $1.97
- Resistance Level
- TCS $4.22
- CANF $2.14
- Average True Range (ATR)
- TCS 0.51
- CANF 0.18
- MACD
- TCS 0.03
- CANF -0.00
- Stochastic Oscillator
- TCS 15.25
- CANF 17.12
About TCS Container Store (The)
The Container Store Group Inc is a U.S. based specialty retailer of storage and organization products and solutions. It offers a collection of multifunctional and customizable storage and organization solutions. The company consists of two segments., The Container store segment consists of retail stores, website, and call center, as well as installation and organizational services business. The Elfa segment involves designing and manufacturing component-based shelving and drawer systems and made-to-measure sliding doors. It derives a majority of the revenue from the Container store segment.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).